Elicera Therapeutics AB

ELIC

SE0015382080

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 16:20:03 31/05/2024 BST			5-day change	1st Jan Change
0.972 ^SEK	+3.40%		+4.29%	-78.68%

05-29	Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA	CI
05-27	Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BioStock: Full speed ahead for Elicera in 2024

February 19, 2024 at 07:35 am

Elicera Therapeutics has kicked off the year in boost mode. The Swedish cell and gene therapy company will get moving on the newly approved phase I/IIa study with lead CAR T candidate ELC-301, made possible by a major financing round coming later this month. Speaking to Elicera's CEO Jamal El-Mosleh, it's clear that the company is ready for a busy 2024, where now two pipeline candidates are in the clinic.

Read the full interview with Jamal El-Mosleh at biostock.se:

https://www.biostock.se/en/2024/02/full-speed-ahead-for-elicera-in-2024/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/elicera-therapeutics/r/biostock-full-speed-ahead-for-elicera-in-2024,c3931066

Latest news about Elicera Therapeutics AB

Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA	05-29	CI
Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-27	CI
Elicera Therapeutics AB Announces Director Changes	03-28	CI
Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies	03-06	CI
Elicera Therapeutics AB to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1	02-16	CI
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301	02-14	CI
Elicera Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-13	CI
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-13	CI
Swedish Regulator OKs Elicera’s Clinical Trial for Lymphoma Therapy	02-09	MT
Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma	02-09	CI
Elicera Therapeutics AB Participates in A Collaborative Project for the Development of Improved Car T-Cell Production That Has Been Awarded Research Support of SEK 850 Thousand	01-09	CI
Elicera Therapeutics AB Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research	12-22	CI
Elicera Therapeutics AB Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application	12-22	CI
Elicera Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Elicera Therapeutics AB Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024	31/10/23	CI
Elicera Therapeutics to Receive Chinese Patent for iTANK Platform	08/09/23	MT
Elicera Therapeutics Receives Notice of Allowance for Chinease Patent Protecting the iTANK Platform	08/09/23	CI
Elicera Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/08/23	CI
Elicera Therapeutics AB Announces the Publication of a Scientific Article in the ELC-401 Program	10/08/23	CI
Elicera Therapeutics to Receive European Patent for iTANK Platform	11/07/23	MT
Elicera Therapeutics AB Receives Notice of Allowance for European Patent Protecting the iTANK	11/07/23	CI
Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23	CI
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on its CAR T-Cell Clinical Trial Application to Test ELC-301 (CARMA- Study)	28/04/23	CI
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	17/02/23	CI
Elicera Therapeutics AB Submits Clinical Trial Application to Evaluate Its CAR T-Cell Therapy in B-Cell Lymphoma	26/01/23	CI

Chart Elicera Therapeutics AB

Duration

Period

More charts

Company Profile

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.

Sector

Pharmaceuticals

Calendar

15/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELICERA THERAPEUTICS AB	-78.68%	3.24M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals

Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Pharmaceuticals

BioStock: Full speed ahead for Elicera in 2024

Latest news about Elicera Therapeutics AB

Chart Elicera Therapeutics AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals